Home|Journals|Articles by Year|Audio Abstracts RSS - TOC
 




Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study

Halil Taskaynatan, Yuksel Kucukzeybek, Yasar Yildiz, Tarik Salman, Utku Oflazoglu, Umut Varol, Ahmet Alacacioglu, Seray Saray, Ozlem Ozdemir, Mustafa Oktay Tarhan.




Abstract
Cited by 0 Articles

Aim: Oral etoposide dosage is roughly 50-100 mg/m2 on days 1 to 21 every 28 days. However, dosage of 50 mg/day oral etoposide for five days a week is not well published. The present study, aimed to evaluate the efficacy and toxicity profile of low dose oral etoposide regimen (50 mg/day on days 1 to 5 every week) in platinum-resistant epithelial ovarian cancer (EOC).
Material and Methods: This study retrospectively evaluates patients with pathologically confirmed platinum-resistant EOC who were unable to tolerate the standard oral etoposide regimen and were on low dose (d1-5/7) oral etoposide regimen in third line or beyond within the period between 2006 and 2014.
Results: The overall response rate among 33 EOC patients was 15.1% while clinical benefit rate was 42.4% (stable disease in 27.3% and partial response in 15.1%). Median progression-free survival was 4 months (95% confidence interval [CI], 2.8–5.1 months) and median overall survival was 12 months (95% CI, 8.8–15.1 months).
Conclusion: We concluded that low dose oral etoposide (50 mg/day, on days 1 to 5 every week) was effective and well tolerated for platinum-resistant EOC.

Key words: Epithelial ovarian cancer; oral etoposide; recurrence






Full-text options


Share this Article



Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Review(er)s Central
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.